Zoek in het archief
 
terug

Check the original
News breaking: 2017-07-16

Pharnext presenteert gegevens rond PXT864 op Alzheimer’s Association International Conference 2017

11:25 uur 11-07-2017

Pharnext presenteert gegevens rond PXT864 op Alzheimer’s Association International Conference 2017

PARIJS–(BUSINESS WIRE)– –Pharnext SA (Paris:ALPHA) (FR00111911287 – ALPHA), een biofarmaceutisch bedrijf met een vernieuwende benadering van geneesmiddelen door reeds bekende medicijnen te combineren en te herpositioneren, heeft vandaag een presentatie aangekondigd van gegevens met betrekking tot de ontwikkeling van de PLEODRUG™ PXT864 voor de behandeling  van de ziekte van Alzheimer. De resultaten worden in een posterpresentatie bekendgemaakt op de Alzheimer’s Association International Conference 2017 (AAIC), die van 16 tot 20 juli in Londen plaatsvindt.

 

 

Pharnext to Present PXT864 Data at the Alzheimer’s Association International Conference 2017

PARIS–(BUSINESS WIRE)– Regulatory News:

Pharnext SA (Paris:ALPHA) (FR00111911287 – ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that data related to PXT864, the Company’s lead PLEODRUG™, in development for the treatment of Alzheimer’s disease (AD), will be presented in two posters at the Alzheimer’s Association International Conference 2017 (AAIC), July 16-20, in London, England.

Details are as follow:

Date

Time

Title

Monday

July 17,

2017

9:30am to

4:15pm BST

Poster #P2-005 

“Treatment with PXT864 Showed Stabilisation of Cognitive Disability in Mild

Alzheimer’s Disease after 36 Weeks.” J. Touchon et al.

Tuesday

July 18,

2017

9:30am to

4:15pm BST

Poster #P3-047 

“A Combination of Acamprosate and Baclofen (PXT864) Synergizes with

Standards of Care for the Treatment of Alzheimer’s Disease.” N. Cholet et al.

PXT864 is a novel synergistic combination of baclofen and acamprosate given as a pill twice-daily. PXT864 acts through a new mechanism of action that targets metabolic imbalance in the brain of patients suffering from neurodegenerative diseases. PXT864’s most advanced indication is Alzheimer’s disease. Development in other neurodegenerative diseases, including Parkinson’s disease and amyotrophic lateral sclerosis (ALS), is also planned.

About Pharnext

Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.

The company Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR00111911287).

For more information, visit www.pharnext.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20170710005599/en/

Contacts

Pharnext

Pierre Schwich, +33 (0)1 41 09 22 30

Chief Financial Officer

investors@pharnext.com

or

In vestor Relations (Europe)

MC Services AG

Anne Hennecke, +49 211 529252 22

anne.hennecke@mc-services.eu

or

Media Relations (Europe)

ALIZE RP

Caroline Carmagnol

Margaux Pronost

+33 (0)1 44 54 36 64

pharnext@alizerp.com

or

Pharne xt

René Goedkoop, +33 (0)1 41 09 22 30

Chief Medical Officer

contact@pharnext.com

or

Invest or Relations (U.S.)

Stern Investor Relations, Inc.

Sarah McCabe, +1 212-362-1200

sarah@sternir.com

or

Media Relations (U.S.)

Russo Partners

Tony Russo

Scott Santiamo

+1 212-845-4251

+1 718-344-5843

tony.russo@russopartnersllc.com

scott.Santiamo@russopartnersll c.com

or

Financial Communication (France)

NewCap

Emmanuel Huyn, +33 (0)1 44 71 20 40

pharnext@newcap.eu

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.